Skip to main content
. 2022 Nov 18;14(11):2558. doi: 10.3390/v14112558

Figure 2.

Figure 2

HIV RNA titer and proportion (%) of HIV RNA < 20 copies/mL in treatment naïve and switching group at baseline and 6- and 12-month follow-up after DTG/3TC treatment was started. (A) HIV RNA titer of the treatment-naïve group at baseline and 6- and 12-month follow-up; (B) HIV RNA titer of the switching group at baseline and 6- and 12-month follow-up. * p < 0.001 compared to the baseline. ** p < 0.001 compared to the baseline.